Robert Glynne-Jones

Summary

Country: UK

Publications

  1. ncbi Rectal cancer: what can we learn from the Dutch TME Study? How will this study impact on current practice in the U.K?
    Rob Glynne-Jones
    Clin Oncol (R Coll Radiol) 14:170-3. 2002
  2. ncbi Can I look at my list? An evaluation of a 'prompt sheet' within an oncology outpatient clinic
    R Glynne-Jones
    Barnet and Chase Farm NHS Trust, London, UK
    Clin Oncol (R Coll Radiol) 18:395-400. 2006
  3. ncbi "Mind the gap"--the impact of variations in the duration of the treatment gap and overall treatment time in the first UK Anal Cancer Trial (ACT I)
    Rob Glynne-Jones
    Mount Vernon Centre for Cancer Treatment, Northwood, UK
    Int J Radiat Oncol Biol Phys 81:1488-94. 2011
  4. ncbi Locally advanced rectal cancer: a comparison of management strategies
    Robert Glynne-Jones
    Centre for Cancer Treatment, Mount Vernon Hospital, Northwood, Middlesex, UK
    Drugs 71:1153-77. 2011
  5. ncbi A phase I/II study of irinotecan when added to 5-fluorouracil and leucovorin and pelvic radiation in locally advanced rectal cancer: a Colorectal Clinical Oncology Group Study
    R Glynne-Jones
    Mount Vernon Cancer Centre, Mount Vernon Hospital, Rickmansworth Road, Northwood, Middlesex HA6 2RN, UK
    Br J Cancer 96:551-8. 2007
  6. ncbi Neoadjuvant cisplatin chemotherapy before chemoradiation: a flawed paradigm?
    Rob Glynne-Jones
    Mount Vernon Centre for Cancer Treatment, Northwood, Middlesex, United Kingdom
    J Clin Oncol 25:5281-6. 2007
  7. ncbi Alternative clinical end points in rectal cancer--are we getting closer?
    R Glynne-Jones
    Centre for Cancer Treatment, Mount Vernon Hospital, Northwood, Middlesex, UK
    Ann Oncol 17:1239-48. 2006
  8. ncbi The integration of oral capecitabine into chemoradiation regimens for locally advanced rectal cancer: how successful have we been?
    R Glynne-Jones
    Mount Vernon Cancer Centre, Northwood, London, UK
    Ann Oncol 17:361-71. 2006
  9. ncbi Neoadjuvant chemotherapy prior to preoperative chemoradiation or radiation in rectal cancer: should we be more cautious?
    R Glynne-Jones
    Mount Vernon Cancer Centre, Northwood, Middlesex, HA6 2RN, UK
    Br J Cancer 94:363-71. 2006
  10. ncbi Complete clinical response after preoperative chemoradiation in rectal cancer: is a "wait and see" policy justified?
    R Glynne-Jones
    Centre for Cancer Treatment, Mount Vernon Hospital, Northwood, Middlesex, United Kingdom
    Dis Colon Rectum 51:10-9; discussion 19-20. 2008

Collaborators

Detail Information

Publications33

  1. ncbi Rectal cancer: what can we learn from the Dutch TME Study? How will this study impact on current practice in the U.K?
    Rob Glynne-Jones
    Clin Oncol (R Coll Radiol) 14:170-3. 2002
  2. ncbi Can I look at my list? An evaluation of a 'prompt sheet' within an oncology outpatient clinic
    R Glynne-Jones
    Barnet and Chase Farm NHS Trust, London, UK
    Clin Oncol (R Coll Radiol) 18:395-400. 2006
    ....
  3. ncbi "Mind the gap"--the impact of variations in the duration of the treatment gap and overall treatment time in the first UK Anal Cancer Trial (ACT I)
    Rob Glynne-Jones
    Mount Vernon Centre for Cancer Treatment, Northwood, UK
    Int J Radiat Oncol Biol Phys 81:1488-94. 2011
    ..The present study retrospectively examines the impact of the recommended 6-week treatment gap and local RT boost on long-term outcome...
  4. ncbi Locally advanced rectal cancer: a comparison of management strategies
    Robert Glynne-Jones
    Centre for Cancer Treatment, Mount Vernon Hospital, Northwood, Middlesex, UK
    Drugs 71:1153-77. 2011
    ..Improvement in the quality of surgery is also an important future goal...
  5. ncbi A phase I/II study of irinotecan when added to 5-fluorouracil and leucovorin and pelvic radiation in locally advanced rectal cancer: a Colorectal Clinical Oncology Group Study
    R Glynne-Jones
    Mount Vernon Cancer Centre, Mount Vernon Hospital, Rickmansworth Road, Northwood, Middlesex HA6 2RN, UK
    Br J Cancer 96:551-8. 2007
    ..The tumour downstaging and complete resection rates (negative CRM) are encouragingly high for this very locally advanced group...
  6. ncbi Neoadjuvant cisplatin chemotherapy before chemoradiation: a flawed paradigm?
    Rob Glynne-Jones
    Mount Vernon Centre for Cancer Treatment, Northwood, Middlesex, United Kingdom
    J Clin Oncol 25:5281-6. 2007
    ..Future meta-analyses should compare induction CT followed by RT and induction followed by CRT versus RT or CRT alone...
  7. ncbi Alternative clinical end points in rectal cancer--are we getting closer?
    R Glynne-Jones
    Centre for Cancer Treatment, Mount Vernon Hospital, Northwood, Middlesex, UK
    Ann Oncol 17:1239-48. 2006
    ..We will propose measurement and analytical techniques for minimising bias and intra- and inter-observer variability of the non-validated end points in the hope of basing these judgements on as firm a ground as possible...
  8. ncbi The integration of oral capecitabine into chemoradiation regimens for locally advanced rectal cancer: how successful have we been?
    R Glynne-Jones
    Mount Vernon Cancer Centre, Northwood, London, UK
    Ann Oncol 17:361-71. 2006
    ..Data from phase I/II single-agent and combination capecitabine chemoradiation studies provide a clear rationale for replacing infusional 5-FU with oral capecitabine as part of chemoradiation for patients with LARC...
  9. ncbi Neoadjuvant chemotherapy prior to preoperative chemoradiation or radiation in rectal cancer: should we be more cautious?
    R Glynne-Jones
    Mount Vernon Cancer Centre, Northwood, Middlesex, HA6 2RN, UK
    Br J Cancer 94:363-71. 2006
    ..The evidence base suggests that concurrent CRT with early positioning of radiotherapy appears the best option for patients with locally advanced rectal cancer and in all disease sites where radiation is the primary local therapy...
  10. ncbi Complete clinical response after preoperative chemoradiation in rectal cancer: is a "wait and see" policy justified?
    R Glynne-Jones
    Centre for Cancer Treatment, Mount Vernon Hospital, Northwood, Middlesex, United Kingdom
    Dis Colon Rectum 51:10-9; discussion 19-20. 2008
    ....
  11. ncbi Locally advanced rectal cancer: what is the evidence for induction chemoradiation?
    Rob Glynne-Jones
    Mount Vernon Centre for Cancer Treatment, Northwood, Middlesex, United Kingdom, HA6 2RN
    Oncologist 12:1309-18. 2007
    ....
  12. ncbi The multidisciplinary management of gastrointestinal cancer. Multimodal treatment of rectal cancer
    Rob Glynne-Jones
    Mount Vernon Cancer Centre, Rickmansworth Road, Northwood HA6 2RN, UK
    Best Pract Res Clin Gastroenterol 21:1049-70. 2007
    ..Multidisciplinary teams achieve the best results. This paper discusses the surgical management of rectal cancer, the pathology, the principles of imaging, and the lessons learnt from randomized trials of radiotherapy and chemoradiation...
  13. ncbi EXTRA--a multicenter phase II study of chemoradiation using a 5 day per week oral regimen of capecitabine and intravenous mitomycin C in anal cancer
    Rob Glynne-Jones
    Mount Vernon Cancer Centre, Mount Vernon Hospital, Middlesex, United Kingdom
    Int J Radiat Oncol Biol Phys 72:119-26. 2008
    ..This phase II trial aimed to determine the feasibility, toxicity, and efficacy of capecitabine, MMC and radiotherapy (RT) in anal cancer patients...
  14. ncbi Cetuximab and chemoradiation for rectal cancer--is the water getting muddy?
    Rob Glynne-Jones
    Mount Vernon Cancer Centre, Northwood, Middlesex, UK
    Acta Oncol 49:278-86. 2010
    ..This review examines the clinical evidence and potential mechanisms for an interaction when EGFR inhibitors are added to fluoropyrimidine-based chemoradiation in rectal adenocarcinoma...
  15. ncbi Antiepidermal growth factor receptor radiosensitizers in rectal cancer
    Robert Glynne-Jones
    Mount Vernon Cancer Centre, Northwood, Middlesex, UK
    Anticancer Drugs 22:330-40. 2011
    ..8% (49/353). A better understanding of the mechanisms involved in combining chemotherapy and radiotherapy might allow more effective future scheduling of biological and chemical agents in combination with radiation...
  16. ncbi Could a wait and see policy be justified in T3/4 rectal cancers after chemo-radiotherapy?
    Robert Hughes
    Mount Vernon Centre for Cancer Treatment, Northwood, Middlesex HA6 2RN, UK
    Acta Oncol 49:378-81. 2010
    ..The present retrospective study aimed to determine whether similar rates of local disease control are seen in a UK cancer centre in patients with T3-4 tumours, who obtained a cCR after preoperative CRT, but did not undergo surgery...
  17. ncbi Improving chemoradiotherapy in rectal cancer
    R Glynne-Jones
    Mount Vernon Hospital, London, UK
    Oncologist 6:29-34. 2001
    ..Oral chemotherapy has the additional advantage of simplifying chemoradiation and providing a treatment that is more appealing to patients...
  18. ncbi A phase I dose escalation study of continuous oral capecitabine in combination with oxaliplatin and pelvic radiation (XELOX-RT) in patients with locally advanced rectal cancer
    R Glynne-Jones
    Mount Vernon Cancer Centre, Northwood, London, UK
    Ann Oncol 17:50-6. 2006
    ..To determine the maximum tolerated dose (MTD) of continuous oral capecitabine plus oxaliplatin and pre-operative pelvic radiotherapy (XELOX-RT)...
  19. ncbi The clinical significance of the circumferential resection margin following preoperative pelvic chemo-radiotherapy in rectal cancer: why we need a common language
    R Glynne-Jones
    Centre for Cancer Treatment, Mount Vernon Hospital, Northwood, Middlesex, UK
    Colorectal Dis 8:800-7. 2006
    ....
  20. ncbi The reliability of lymph-node staging in rectal cancer after preoperative chemoradiotherapy
    M Beresford
    Mount Vernon Cancer Centre, Northwood, Middlesex, UK
    Clin Oncol (R Coll Radiol) 17:448-55. 2005
    ..To determine the prognostic significance of the nodal stage and number of nodes recovered in the surgical specimen after preoperative synchronous chemoradiation (SCRT) and surgery for locally advanced or unresectable rectal cancer...
  21. ncbi Chemo-radiotherapy: an alternative to surgery for squamous cell carcinoma of the rectum--report of six patients and literature review
    S Rasheed
    Northwick Park and St Mark s Hospitals, Harrow, Middlesex, UK
    Colorectal Dis 11:191-7. 2009
    ....
  22. ncbi Chemoradiation schedules--what radiotherapy?
    R Glynne-Jones
    Mount Vernon Cancer Centre, Northwood, Middlesex HA6 2RN, UK
    Eur J Cancer 38:258-69. 2002
    ....
  23. ncbi A phase I/II study of CHARTWEL with concurrent chemotherapy in locally advanced, inoperable carcinoma of the oesophagus
    J Harney
    Marie Curie Research Wing, Mount Vernon Hospital, Northwood, Middlesex, UK
    Clin Oncol (R Coll Radiol) 15:109-14. 2003
    ..To evaluate the feasibility, efficacy and toxicity of concurrent chemotherapy and continuous, hyperfractionated, accelerated radiotherapy weekend less (CHARTWEL) in the treatment of locally advanced, inoperable oesophageal cancer...
  24. ncbi Delaying surgery after neoadjuvant chemoradiotherapy for rectal cancer may reduce postoperative morbidity without compromising prognosis
    S F Kerr
    Centre for Cancer Treatment, Mount Vernon Hospital, Northwood HA62RN, UK
    Br J Surg 95:1534-40. 2008
    ..This retrospective study investigated whether the interval between neoadjuvant chemoradiotherapy and surgery for rectal cancer influences postoperative morbidity or prognosis...
  25. ncbi Assessment of microvessel density and carbonic anhydrase-9 (CA-9) expression in rectal cancer
    S Rasheed
    Department of Surgery, St Mark s Hospital, Harrow, Middlesex, UK
    Pathol Res Pract 205:1-9. 2009
    ..Using the largest cohort of rectal adenocarcinomas to date, this study aimed to assess microvessel density (MVD) and carbonic anhydrase-9 (CA-9) expression and to correlate the results with recurrence and cancer-specific survival...
  26. ncbi Hypoxia-inducible factor-1alpha and -2alpha are expressed in most rectal cancers but only hypoxia-inducible factor-1alpha is associated with prognosis
    S Rasheed
    Department of Surgery, St Mark s Hospital, Harrow, Middlesex, UK
    Br J Cancer 100:1666-73. 2009
    ..Our results indicate that HIF-1alpha, but not HIF-2alpha, might be used as a marker of prognosis, in addition to methods currently used, to enhance patient management...
  27. ncbi The impact of surgically induced ischaemia on protein levels in patients undergoing rectal cancer surgery
    G K Atkin
    Gray Cancer Institute, Mount Vernon Hospital, Northwood, Middlesex HA6 2RN, UK, and Karmanos Cancer Institute, Wayne State University, Detroit, MI 48201 2013, USA
    Br J Cancer 95:928-33. 2006
    ..Although rectal cancer was the studied model, the results may be applicable to any solid tumour undergoing extirpation in which molecular markers have been proposed to guide patient therapy...
  28. ncbi The effect of surgically induced ischaemia on gene expression in a colorectal cancer xenograft model
    G Atkin
    Gray Cancer Institute, Mount Vernon Hospital, Northwood, Middlesex HA6 2RN, UK
    Br J Cancer 94:121-7. 2006
    ....
  29. ncbi Can histopathologic assessment of circumferential margin after preoperative pelvic chemoradiotherapy for T3-T4 rectal cancer predict for 3-year disease-free survival?
    Suzannah Mawdsley
    Mount Vernon Cancer Centre, Northwood, Middlesex, United Kingdom
    Int J Radiat Oncol Biol Phys 63:745-52. 2005
    ....
  30. ncbi Just how useful an endpoint is complete pathological response after neoadjuvant chemoradiation in rectal cancer?
    Rob Glynne-Jones
    Int J Radiat Oncol Biol Phys 66:319-20. 2006
  31. ncbi Role of neoadjuvant chemotherapy in rectal cancer: interpretation of the EXPERT study
    Rob Glynne-Jones
    J Clin Oncol 24:4664-5; author reply 4665-6. 2006
  32. ncbi Anal cancer: the end of the road for neoadjuvant chemoradiotherapy?
    Rob Glynne-Jones
    Mount Vernon Cancer Centre, Northwood, Middlesex, United Kingdom
    J Clin Oncol 26:3669-71. 2008
  33. ncbi Correlation of spectral imaging and visual grading for the quantification of thymidylate synthase protein expression in rectal cancer
    Gary Atkin
    Gray Cancer Institute, Mount Vernon Hospital, Northwood, HA6 2RN Middlesex, UK
    Hum Pathol 36:1302-8. 2005
    ....